Protein biomarkers in renal transplantation

Chakraborty, Arjun; Sarwal, Minnie M.

doi:10.1080/14789450.2018.1396892

Cited by 9 publications

(9 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammation-induced cytokines could be a major impediment for tolerance and the primary determining factor for allograft rejection. Chakraborty and Sarwal ( 201 ) have extensively reviewed cyto- and chemokine biomarkers in Kidney Tx. Karxzewski et al.…”

Section: Inflammation Biomarkers: Dynamic Role Of Il-6mentioning

confidence: 99%

The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?

Ravindranath

Hilali²,

Filippone

2021

Front. Immunol.

View full text Add to dashboard Cite

Transplantation (Tx) remains the optimal therapy for end-stage disease (ESD) of various solid organs. Although alloimmune events remain the leading cause of long-term allograft loss, many patients develop innate and adaptive immune responses leading to graft tolerance. The focus of this review is to provide an overview of selected aspects of the effects of inflammation on this delicate balance following solid organ transplantation. Initially, we discuss the inflammatory mediators detectable in an ESD patient. Then, the specific inflammatory mediators found post-Tx are elucidated. We examine the reciprocal relationship between donor-derived passenger leukocytes (PLs) and those of the recipient, with additional emphasis on extracellular vesicles, specifically exosomes, and we examine their role in determining the balance between tolerance and rejection. The concept of recipient antigen-presenting cell “cross-dressing” by donor exosomes is detailed. Immunological consequences of the changes undergone by cell surface antigens, including HLA molecules in donor and host immune cells activated by proinflammatory cytokines, are examined. Inflammation-mediated donor endothelial cell (EC) activation is discussed along with the effect of donor-recipient EC chimerism. Finally, as an example of a specific inflammatory mediator, a detailed analysis is provided on the dynamic role of Interleukin-6 (IL-6) and its receptor post-Tx, especially given the potential for therapeutic interdiction of this axis with monoclonal antibodies. We aim to provide a holistic as well as a reductionist perspective of the inflammation-impacted immune events that precede and follow Tx. The objective is to differentiate tolerogenic inflammation from that enhancing rejection, for potential therapeutic modifications. (Words 247).

show abstract

Section: Inflammation Biomarkers: Dynamic Role Of Il-6mentioning

confidence: 99%

The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?

Ravindranath

Hilali²,

Filippone

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In clinical practice, serum creatinine, estimated glomerular filtration rate (eGFR), and urinary albumin/protein excretion are the current biomarkers of kidney damage. These parameters are easy to measure, non-invasive, and interpretable, but apply to a later stage of the disease; they are neither sensitive nor specific, and are not connected with the molecular pathophysiology [ 5 ]. Thus, there is a need for accurate novel noninvasive biomarkers for continuous monitoring after KT and early diagnosis of allograft dysfunction, which in turn may lead to an improvement in the clinical outcome.…”

Section: Introductionmentioning

confidence: 99%

Biomarker-Development Proteomics in Kidney Transplantation: An Updated Review

Sirolli

Piscitani

Bonomini

2023

IJMS

View full text Add to dashboard Cite

Kidney transplantation (KT) is the optimal therapeutic strategy for patients with end-stage renal disease. The key to post-transplantation management is careful surveillance of allograft function. Kidney injury may occur from several different causes that require different patient management approaches. However, routine clinical monitoring has several limitations and detects alterations only at a later stage of graft damage. Accurate new noninvasive biomarker molecules are clearly needed for continuous monitoring after KT in the hope that early diagnosis of allograft dysfunction will lead to an improvement in the clinical outcome. The advent of “omics sciences”, and in particular of proteomic technologies, has revolutionized medical research. Proteomic technologies allow us to achieve the identification, quantification, and functional characterization of proteins/peptides in biological samples such as urine or blood through supervised or targeted analysis. Many studies have investigated proteomic techniques as potential molecular markers discriminating among or predicting allograft outcomes. Proteomic studies in KT have explored the whole transplant process: donor, organ procurement, preservation, and posttransplant surgery. The current article reviews the most recent findings on proteomic studies in the setting of renal transplantation in order to better understand the effective potential of this new diagnostic approach.

show abstract

“…With that goal in mind, diverse biomarkers present in biofluids have been pointed out, as reviewed, e.g., by Eikmans et al [ 35 ], Erpicume et al [ 36 ], and Chakraborty and Sarwal [ 35 , 36 , 37 ]. However, none of these biomarkers have, to date and to the best of our knowledge, been used in regular clinical environments.…”

Section: Introductionmentioning

confidence: 99%

Proteomics for Biomarker Discovery for Diagnosis and Prognosis of Kidney Transplantation Rejection

et al. 2022

View full text Add to dashboard Cite

Renal transplantation is currently the treatment of choice for end-stage kidney disease, enabling a quality of life superior to dialysis. Despite this, all transplanted patients are at risk of allograft rejection processes. The gold-standard diagnosis of graft rejection, based on histological analysis of kidney biopsy, is prone to sampling errors and carries high costs and risks associated with such invasive procedures. Furthermore, the routine clinical monitoring, based on urine volume, proteinuria, and serum creatinine, usually only detects alterations after graft histologic damage and does not differentiate between the diverse etiologies. Therefore, there is an urgent need for new biomarkers enabling to predict, with high sensitivity and specificity, the rejection processes and the underlying mechanisms obtained from minimally invasive procedures to be implemented in routine clinical surveillance. These new biomarkers should also detect the rejection processes as early as possible, ideally before the78 clinical outputs, while enabling balanced immunotherapy in order to minimize rejections and reducing the high toxicities associated with these drugs. Proteomics of biofluids, collected through non-invasive or minimally invasive analysis, e.g., blood or urine, present inherent characteristics that may provide biomarker candidates. The current manuscript reviews biofluids proteomics toward biomarkers discovery that specifically identify subclinical, acute, and chronic immune rejection processes while allowing for the discrimination between cell-mediated or antibody-mediated processes. In time, these biomarkers will lead to patient risk stratification, monitoring, and personalized and more efficient immunotherapies toward higher graft survival and patient quality of life.

show abstract

Protein biomarkers in renal transplantation

Cited by 9 publications

References 114 publications

The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?

The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?

Biomarker-Development Proteomics in Kidney Transplantation: An Updated Review

Proteomics for Biomarker Discovery for Diagnosis and Prognosis of Kidney Transplantation Rejection

Contact Info

Product

Resources

About